Premium
A novel nicotinic acid‐based dietary supplement reduced triacylglycerides in healthy, hyperlipidemic adults
Author(s) -
Rockway Susie W.,
Kalman Douglas,
Rubin Samantha,
Feldman Lori,
Krieger Diane R.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.lb87-c
Subject(s) - placebo , niacin , medicine , overweight , adverse effect , cholesterol , randomized controlled trial , obesity , endocrinology , alternative medicine , pathology
Nicotinic acid, once the first choice for treating lipidemia, has diminished popularity due to uncomfortable side affects (flushing). The purpose of this study was to determine if a product containing nicotinic acid plus chitosan would affect lipids over an eight‐week period. Thirty‐two, overweight, lipidemic subjects (22 female, 10 male) were randomized to intervention or placebo and instructed not to change their lifestyle. Results were based on 24 subjects (per‐protocol analysis). After 8 weeks, the treatment group reduced total cholesterol by 15.2 mg/dl (p=0.070), LDL cholesterol by 9.5 mg/dl, yet neither were significantly different from placebo. No significant changes occurred in HDL in either group. However, triglycerides were significantly reduced (p=0.009) in the treatment group compared to baseline and to placebo (p=0.027). In conclusion, the product tested induced a 14% reduction in TG with trends for positively impacting TC. There were no differences in adverse events. It appears that this product reduces risk factors for CVD, though follow‐up studies in larger sample sizes are suggested. Product and funding was provided by PharmaNutrients, Inc.